Home

Johnson & Johnson (JNJ)

191.17
+0.00 (0.00%)
NYSE · Last Trade: Oct 16th, 5:31 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Johnson & Johnson Battles New UK Talc Cancer Claims Worth £1B After Massive US Verdict: Reportstocktwits.com
Meanwhile, analysts raised price targets on the stock following strong Q3 results and the planned orthopedic spin-off.
Via Stocktwits · October 15, 2025
Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds
New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major indices like the Nasdaq and S&P 500 managed to eke out modest gains, the Dow's struggle underscores an underlying apprehension
Via MarketMinute · October 15, 2025
Dow Jones Stumbles Amidst Global Headwinds, Reflecting Cautious Market Sentiment
The Dow Jones Industrial Average (DJIA) concluded a volatile trading day on Wednesday, October 15, 2025, with a fractional dip, signaling a cautious, if not overtly negative, sentiment pervading the broader market. While the tech-heavy Nasdaq and the benchmark S&P 500 managed to eke out modest gains, the Dow's
Via MarketMinute · October 15, 2025
Johnson & Johnson To Separate Its Orthopedic Businessstocktwits.com
Via Stocktwits · October 14, 2025
Dividend Defenders: How Two Stalwart Stocks Weathered April's Market Squall
As the calendar turned to April 2025, financial markets found themselves in a precarious position, teetering on the brink of a full-blown bear market. Investor fears, fueled by persistent inflation, aggressive interest rate hikes, and escalating geopolitical tensions, coalesced into a potent wave of pessimism that briefly dragged the S&
Via MarketMinute · October 15, 2025
Dividend Duo Delights Investors: Meta Platforms and Johnson & Johnson Shine in 2025
In a year marked by evolving market dynamics and a persistent search for both growth and stability, two distinct titans of industry—Meta Platforms (NASDAQ: META) and Johnson & Johnson (NYSE: JNJ)—have emerged as standout performers for dividend-seeking investors. As of October 15, 2025, these companies represent compelling examples of
Via MarketMinute · October 15, 2025
Wall Street's Earnings Momentum Fades, Market Dips Amidst Trade Tensions
Wall Street witnessed a significant shift this Wednesday as an eagerly anticipated earnings push ultimately petered out, sending stocks into the red. This downturn followed a volatile Tuesday, which saw markets grappling with fresh developments in the ongoing U.S.-China trade saga. Despite earlier indications of a rebound with
Via MarketMinute · October 15, 2025
These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earningsbenzinga.com
Via Benzinga · October 15, 2025
2 Dividend Stocks I'm Very Thankful I Owned This Yearfool.com
I don't intend to sell my shares of these companies anytime soon.
Via The Motley Fool · October 15, 2025
Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analystbenzinga.com
Johnson & Johnson raised its 2025 revenue guidance as Stelara erosion slowed, while BofA maintained a Neutral rating citing fair valuation.
Via Benzinga · October 15, 2025
Johnson & Johnson Stock Can Keep Rising as Strategy Pays Offmarketbeat.com
Johnson & Johnson (NYSE: JNJ) beat Q3 estimates, raised revenue guidance, and plans an orthopedics spin-off—analysts see up to 50% upside for JNJ stock.
Via MarketBeat · October 15, 2025
2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 41% in 12 Months, According to Select Wall Street Analystsfool.com
Juicy dividends are only part of the attraction with these beaten-down stocks.
Via The Motley Fool · October 15, 2025
New Jersey Rep. Thomas Kean Sold Up to $215K Worth of Franklin Resources Stockbenzinga.com
Via Benzinga · October 15, 2025
This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buyfool.com
Johnson & Johnson has a very healthy financial profile and growth prospects.
Via The Motley Fool · October 15, 2025
Powell Calms the Markets While Trade Tensions Keep Investors on Edgechartmill.com
A dovish tone from Fed Chair Jerome Powell helped Wall Street recover from early losses, but U.S.–China tensions under President Trump’s renewed tariff threats kept sentiment fragile. Strong bank earnings added mixed signals to an already volatile session.
Via Chartmill · October 15, 2025
AI Revolutionizes Quality Control: A New Era of Precision and Speed in Manufacturing, Electronics, and Pharmaceuticals
A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency across critical industries. This new AI tool has made checking the quality of materials significantly easier, with profound and immediate implications for sectors such
Via MarketMinute · October 14, 2025
The Gathering Storm: AI Overbuilding, Trade Wars, and National Debt Fuel Market Crash Fears
As of October 14, 2025, a palpable sense of unease permeates global financial markets, with a growing chorus of analysts and institutions warning of a potential market crash. The prevailing sentiment is a complex mix of resilience in equity markets, particularly in the booming artificial intelligence (AI) sector, juxtaposed with
Via MarketMinute · October 14, 2025
Looking At Johnson & Johnson's Recent Unusual Options Activitybenzinga.com
Via Benzinga · October 14, 2025
Johnson & Johnson To Spin Off Orthopedics Unit After Raising 2025 Sales Forecasttalkmarkets.com
Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings.
Via Talk Markets · October 14, 2025
S&P Drug Titan J&J Dips After Announcing A Surprise Spinoffinvestors.com
The news comes alongside a third-quarter beat and sales guidance hike.
Via Investor's Business Daily · October 14, 2025
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlookbenzinga.com
Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.
Via Benzinga · October 14, 2025
Johnson & Johnson (NYSE:JNJ) Beats Q3 2025 Estimates and Raises Full-Year Sales Outlookchartmill.com
Johnson & Johnson (JNJ) beat Q3 2025 earnings estimates, raised its full-year sales outlook, and announced a planned spin-off of its Orthopedics business.
Via Chartmill · October 14, 2025
Stock Market Today: S&P 500, Nasdaq Futures Tumble Ahead Of Big Bank Earnings—Goldman Sachs, JPMorgan, Citigroup In Focusbenzinga.com
U.S. stock futures declined on Tuesday following Monday’s reversal rally. Futures of major benchmark indices were lower.
Via Benzinga · October 14, 2025
Earnings Scheduled For October 14, 2025benzinga.com
Via Benzinga · October 14, 2025
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Printstocktwits.com
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.
Via Stocktwits · October 14, 2025